LJPC La Jolla Pharmaceutical Dashboard

La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.

Company profile

Ticker

LJPC

Exchange

NASDAQ

Website

lajollapharmaceutical.com

CEO

Larry Edwards

Incorporated

California

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Seagen ...

SEC CIK

0000920465

Corporate docs

Articles of Incorporation & Bylaws

IRS number

330361285

LJPC stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

46 Stocks Moving In Thursday's Mid-Day Session

3 Jun 21

Gainers GTT Communications, Inc. (NYSE: GTT) shares jumped 66% to $4.16 on abnormally-high volume. The company’s stock also jumped over 57% on Wednesday.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

3 Jun 21

28 Stocks Moving in Thursday's Pre-Market Session

3 Jun 21

Gainers GTT Communications, Inc. (NYSE: GTT) rose 41.6% to $3.54 in pre-market trading after jumping over 57% on Wednesday.

60 Biggest Movers From Yesterday

27 May 21

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts

14 May 21

Press releases

Pro users get this 30m faster

Thinking about buying stock in La Jolla Pharmaceutical, The GEO Group, Abeona Therapeutics, Sellas Life Sciences, or Naked Brand?

3 Jun 21

NEW YORK, June 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LJPC, GEO, ABEO, SLS, and NAKD.

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress

7 May 21

La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

7 May 21

24 Jun 21

31 Dec 21

Financial summary

Financial statements Chart LJPC financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	38.67M	38.67M	38.67M	38.67M	38.67M	38.67M
Cash burn (monthly)	(positive/no burn)	3.29M	(positive/no burn)	657.08K	(positive/no burn)	684.42K
Cash used (since last report)	n/a	9.16M	n/a	1.83M	n/a	1.91M
Cash remaining	n/a	29.51M	n/a	36.84M	n/a	36.77M
Runway (months of cash)	n/a	9.0	n/a	56.1	n/a	53.7

Beta Read what these cash burn values mean

Recent insider trades

LJPC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Jun 21	Michael S Hearne	Common Stock	Grant	Aquire A	No	No	4.165	148	616.42	4,082
15 Jun 21	Michael S Hearne	Employee Stock Option Common Stock	Grant	Aquire A	No	No	4.9	148	725.2	148
15 Jun 21	Edwards Larry G.	Common Stock	Grant	Aquire A	No	No	4.165	275	1.15K	1,573
15 Jun 21	Edwards Larry G.	Employee Stock Option Common Stock	Grant	Aquire A	No	No	4.9	275	1.35K	275
1 Jun 21	Tang Kevin C	Common Stock	Buy	Aquire P	Yes	No	4.5277	43,734	198.01K	10,049,224
1 Jun 21	Tang Kevin C	Common Stock	Buy	Aquire P	Yes	No	4.292	15,358	65.92K	10,005,490
28 May 21	Michael S Hearne	Common Stock	Grant	Aquire A	No	No	3.655	169	617.69	3,934
28 May 21	Michael S Hearne	Employee Stock Option Common Stock	Grant	Aquire A	No	No	4.3	169	726.7	169
28 May 21	Edwards Larry G.	Common Stock	Grant	Aquire A	No	No	3.655	314	1.15K	1,298
28 May 21	Edwards Larry G.	Employee Stock Option Common Stock	Grant	Aquire A	No	No	4.3	314	1.35K	314

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

LJPC institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

74.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	74	65	+13.8%
Opened positions	15	9	+66.7%
Closed positions	6	6	–
Increased positions	16	19	-15.8%
Reduced positions	22	21	+4.8%

13F shares	Current	Prev Q	Change
Total value	98.79M	94.11M	+5.0%
Total shares	20.53M	20.34M	+0.9%
Total puts	55.9K	25K	+123.6%
Total calls	24.4K	55.8K	-56.3%
Total put/call ratio	2.3	0.4	+411.3%

Largest owners	Shares	Value	Change
Tang Capital Management	9.41M	$39.88M	0.0%
RTW Investments	2.33M	$9.87M	-2.9%
BLK Blackrock	1.5M	$6.36M	+1.4%
Vanguard	978.85K	$4.15M	-6.6%
Boxer Capital	890.7K	$3.78M	0.0%
D. E. Shaw & Co.	731.14K	$3.1M	+75.9%
MS Morgan Stanley	427.68K	$1.81M	+5.5%
Geode Capital Management	416.59K	$1.77M	+3.7%
STT State Street	395.52K	$1.68M	-10.4%
WFC Wells Fargo & Co.	373.76K	$1.59M	+1323.7%

Largest transactions	Shares	Bought/sold	Change
Alyeska Investment	0	-536.85K	EXIT
WFC Wells Fargo & Co.	373.76K	+347.5K	+1323.7%
D. E. Shaw & Co.	731.14K	+315.4K	+75.9%
Millennium Management	175.84K	+175.84K	NEW
Acadian Asset Management	114.95K	+114.95K	NEW
Renaissance Technologies	33.6K	-96.35K	-74.1%
Vanguard	978.85K	-69.57K	-6.6%
RTW Investments	2.33M	-69.48K	-2.9%
First Midwest Bank Trust Division	89.34K	-66.5K	-42.7%
Jacobs Levy Equity Management	131.42K	-61.98K	-32.0%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Biocryst Pharmaceuticals • Protagonist Therapeutics • Blueprint Medicines • Iterum Therapeutics • Entasis Therapeutics

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: advertising, annum, antibacterial, arrangement, assistance, attainment, bundled, cancellable, chief, consulting, deemed, distinct, established, Europe, extent, forgiven, formulation, fully, guaranteed, inception, intrinsic, issuable, licensee, Loan, month, multiplied, National, negotiate, NMPA, nonrefundable, occurrence, oral, PAION, Paycheck, penalty, permitted, point, position, PPP, predominant, Prepaid, promissory, provision, Pte, rebate, refundable, repay, retroactive, satisfied, SBA, separate, Small, speaker, stage, sublease, submission, surveillance, Switzerland, synthetic, uncertainty, unforgiven, United, unsecured, utility, voting, Waltham, withholding

Removed: accurately, adversely, borrowing, Centre, chain, collateral, commencing, Court, disrupt, duration, effectively, escalation, extend, financed, GIAPREZATM, impacted, incremental, inducement, Initial, invested, investing, laboratory, letter, lieu, located, LP, maintain, ongoing, option, outbreak, pandemic, pledged, present, private, produce, restarted, resulted, safety, standby, supporting, therapy, Towne, travel, volatility, wholesaler

From filing 10-Q 2021 Q1